Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pradaxa versus continued antiplatelet therapy in symptomatic intracranial atherosclerotic stenosis with poor antiplatelet response
ChiCTR-OPN-17012503Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dabigatran in Cerebral atherosclerotic stenosis (ICAD) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: ischemic stroke recurrence, hemorrhagic stroke and 6 more. Started Aug 2017; status: recruiting.
02
Drugs
dabigatran
03
Conditions
Cerebral atherosclerotic stenosis (ICAD)
Beyond the preview
Go deeper on ChiCTR-OPN-17012503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17012503.